iNOS Polyclonal Antibody

Inducible nitric oxide synthase (iNOS), also known as NOS2, converts arginine to citrulline and nitric oxide (NO) during the inflammatory response.^1,2 It is composed of an N-terminal oxygenase domain that contains binding sites for its substrate L-arginine (Item No. 23703), heme, and the cofactor tetrahydrobiopterin (BH4), a hinge region that binds calmodulin, and a reductase domain with binding sites for NADPH, flavin mononucleotide (FMN), and FAD. Upon induction by various pro-inflammatory cytokines, including TNF-α, IL-1β, and IFN-γ, or by LPS, iNOS is expressed in macrophages, hepatocytes, smooth muscle cells, chondrocytes, glial cells, astrocytes, neurons, and cardiac myocytes.² iNOS expression is induced via two main signaling pathways: NF-κB and JAK/STAT. It is involved in pathogen defense against bacteria, parasites, and viruses, and its expression is associated with several disease states, including sepsis, cancer, pain, and Parkinson’s disease.^2,3,4,5,6 Cayman's iNOS Polyclonal Antibody can be used for immunohistochemistry (IHC), immunoprecipitation (IP), and Western blot (WB) applications. The antibody recognizes iNOS at 130 kDa from mouse samples.

WARNING This product is not for human or veterinary use.

1. Alderton, W.K., Cooper, C.E., and Knowles, R.G. Nitric oxide synthases: Structure, function, and inhibition. Biochem. J. 357(Pt 3), 593-615 (2001).

2. Cinelli, M.A., Do, H.T., Miley, G.P., et al. Inducible nitric oxide synthase: Regulation, structure, and inhibition. Med. Res. Rev. 40(1), 158-189 (2020).

3. Lanone, S., Manivet, P., Callebert, J., et al. Inducible nitric oxide synthase (NOS2) expressed in septic patients is nitrated on selected tyrosine residues: Implications for enzymic activity. Biochem. J. 366(Pt 2), 399-404 (2002).

4. Ambs, S., Merriam, W.G., Bennett, W.P., et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression. Cancer Res. 58(2), 334-341 (1998).

5. Budziñski, M., Misterek, K., Gumulka, W., et al. Inhibition of inducible nitric oxide synthase in persistent pain. Life Sci. 66(4), 301-305 (2000).

6. Liberatore, G.T., Jackson-Lewis, V., Vukosavic, S., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5(12), 1403-1409 (1999).

Chumanevich, A.A., Witalison, E.E., Chaparala, A., et al. Repurposing the anti-malarial drug, quinacrine: New anti-colitis properties. Oncotarget 7(33), 52928-52939 (2016).

Chen, C.C., Hung, T.H., Lee, C.Y., et al. Berberine protects against neuronal damage via suppression of glia-mediated inflammation in traumatic brain injury. PLoS One 9(12), e115694 (2014).

Nicholson, J.D., Puche, A.C., Guo, Y., et al. PGJ₂ Provides Prolonged CNS Stroke Protection by Reducing White Matter Edema. PLoS One 7(12), e50021 (2012).

Carvalho, C.M., Silverio, J.C., da Silva, A.A., et al. Inducible nitric oxide synthase in heart tissue and nitric oxide in serum of Trypanosoma cruzi-infected rhesus monkeys: association with heart injury. PLoS Negl. Trop. Dis. 6(5), e1644 (2012).

Huang, H.-J., Chen, Y.-H., Liang, K.-C., et al. Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection. PLoS One 7(7), e39656 (2012).

Capaccio, D., Ciccodicola, A., Sabatino, L., et al. A novel germline mutation in peroxisome proliferator-activated receptor g gene associated with large intestine polyp formation and dyslipidemia. Biochim. Biophys. Acta 1802, 572-581 (2010).